TUSTIN, Calif., Oct. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that a detailed report on the Company, its prospects in China, its products and technologies, and its history is available at http://www.ivaluerich.com/profile_company.php?id=3785
"The report includes significant information on investing in Chinese pharmaceutical companies, why AMDL resembles other companies than have been successful, background on the Company's Jade Pharmaceutical subsidiary, our DR-70(R) cancer test kit and our Combination Immunogene Therapy to assist a cancer patient's immune system to attack and kill cancer cells," said Gary Dreher, AMDL CEO. "We believe this information will be of interest to our shareholders and potential investors."
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc.
AMDL Investor R
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.
All rights reserved